The Effect of Race and Gender on Patterns of rt-PA Use Within A Population

Journal of Stroke and Cerebrovascular Diseases

Volumn 12, Issue 5, 2003, Pages 217-220

  Kleindorfer, Dawn ^a,c   Schneider, Alexander ^a   Kissela, Brett M ^a   Woo, Daniel ^a   Khoury, Jane ^a   Alwell, Kathleen ^a   Miller, Rosemary ^d   Gebel, James ^b   Szaflarski, Jerzy ^a   Pancioli, Arthur ^a   Jauch, Edward ^a   Moomaw, Charles ^a   Shukla, Rakesh ^a   Broderick, Joseph P ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

^d NONE

Author keywords

Epidemiology; Gender; Ischemic stroke; Race; Thromolytics; Tpa

Indexed keywords

ALTEPLASE;

ADULT; AGE; AGED; ARTICLE; CAUCASIAN; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DRUG APPROVAL; FEMALE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE DELIVERY; HEALTH CENTER; HUMAN; MALE; MEDICAL DECISION MAKING; NEGRO; PATIENT CARE; POPULATION RESEARCH; PRIORITY JOURNAL; RACE DIFFERENCE; SEX DIFFERENCE; SOCIOECONOMICS; STATISTICAL ANALYSIS; UNIVERSITY HOSPITAL;

EID: 0346122789     PISSN: 10523057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jstrokecerebrovasdis.2003.09.001     Document Type: Article

References (15)

1. NINDS rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1587.
2. Association AH. Heart and Stroke Statistical Update. Dallas, TX, American Heart Association, 2002.
3. Grotta JC, Burgin WS, El-Mitwalli A, et al. Intravenous tissue-type plasminogen activator therapy for ischemic stroke. Arch Neurol 2001;58:2009-2013.
4. Johnston SC, Fung LH, Gillum LA, et al. Utilization of intravenous tissue-type plasminogen activator for ischemic stroke at academic medical centers: The influence of ethnicity. Stroke 2001;32:1061-1068.
5. Reed SD, Cramer SC, Blough DK, et al. Treatment with tissue plasminogen activator and inpatient mortality rates for patients with ischemic stroke treated in community hospitals. Stroke 2001;32:1832-40.
6. Zweifler RM, Brody ML, Graves GC, et al. Intravenous t-PA for acute ischemic stroke: Therapeutic yield of a stroke code system. Neurology 1998;50:501-503.
7. Wang DZ, Rose JA, Honings DS, et al. Treating acute stroke patients with intravenous t-PA. The OSF stroke network experience. Stroke 2000;31:77-81.
8. Engelstein E, Margulies J, Jeret JS. Lack of t-PA use for acute ischemic stroke in a community hospital: High incidence of excusion criteria. Am J Emerg Med 2000;18:257-260.
9. Katzan IL, Furlan AJ, Lloyd LE, et al. Use of tissue-type plasminogen activator for acute ischemic stroke: The Cleveland area experience. JAMA 2000;283:1151-1158.
10. Morgenstern LB, Staub L, Chan W, et al. Improving delivery of acute stroke therapy: The TLL Temple Foundation Stroke Project. Stroke 2002;33:160-166.
11. Broderick J, Brott T, Kothari R, et al. The Greater Cincinnati/Northern Kentucky Stroke Study: Preliminary first-ever and total incidence rates of stroke among blacks. Stroke 1998;29:415-421.
12. Johnston SC, Fung LH, Gillum LA, et al. Utilization of intravenous tissue-type plasminogen activator for ischemic stroke at academic medical centers: the influence of ethnicity. Stroke 2001;32:1061-1068.
13. Tong D, Jsia A, Crisotomo R. Use of rt-PA among Asian Americans: Is there evidence of racial bias? Neurology 2002;58:A73.
14. Grotta JC, Burgin WS, El-Mitwalli A, et al. Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000. Arch Neurol 2001;58:2009-2013.
15. Nilasena D, Kresowik T, Piskac A, et al. Assessing patterns of rPA use in acute stroke. Stroke 2002;33:354 (abstr).